Funding

Trellis Bioscience

United States · Biotech

Developing native human monoclonal antibodies to treat intractable infectious diseases

Visit trellisbio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$9MAMR Action Fund — Role not disclosedEaston Capital — Role not disclosedNew Science Ventures — Role not disclosedThe Doctor Group — Role not disclosed

Investors

AMR Action FundSeries CEaston CapitalSeries CNew Science VenturesSeries CThe Doctor GroupSeries C

Coverage

Jul 16, 2026Trellis Bioscience · Series C

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcestrellisbio.com ↗